Yes, Calquence Treats CLL
Calquence (acalabrutinib) is FDA-approved for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It targets adults with specific disease profiles, including those with or without 17p deletion, as monotherapy or in combination therapy.[1]
How Calquence Fits into CLL Treatment
Calquence is a BTK inhibitor that blocks Bruton's tyrosine kinase, a protein essential for CLL cell survival and proliferation. The FDA first approved it in 2017 for relapsed or refractory CLL after at least one prior therapy. Expanded approvals include:
- First-line treatment for CLL/SLL patients unfit for fludarabine-based therapy (2019).
- First-line combination with obinutuzumab (2023).
- Relapsed/refractory cases after BTK inhibitor or BCL-2 inhibitor therapy (2024).[1][2]
Clinical trials like ELEVATE-TN showed 12-month progression-free survival of 95% in first-line use with obinutuzumab versus 78% for obinutuzumab alone.[2]
Who Qualifies for Calquence in CLL
Eligible patients include:
- Treatment-naive adults.
- Those with relapsed/refractory CLL after prior lines of therapy.
- No requirement for specific genetic markers like 17p deletion, unlike some approvals for competitors.[1]
Dosing is 100 mg orally twice daily, with or without food, until disease progression or toxicity.[1]
Calquence vs. Other BTK Inhibitors for CLL
| Drug | Key CLL Approvals | Dosing | Common Distinctions |
|------|-------------------|--------|---------------------|
| Calquence (acalabrutinib) | First-line monotherapy/combo; relapsed/refractory | 100 mg BID | More selective BTK binding; lower atrial fibrillation risk than ibrutinib[3] |
| Imbruvica (ibrutinib) | First-line; relapsed; high-risk (17p del) | 420 mg QD | First BTK inhibitor; higher cardiovascular side effects[3] |
| Brukinsa (zanubrutinib) | First-line; relapsed; high-risk | 320 mg QD | Similar efficacy; competes on tolerability[3] |
Calquence shows comparable efficacy to ibrutinib in ELEVATE-TN trial (87% vs. 83% 48-month PFS) with fewer discontinuations due to adverse events.[2][3]
Common Side Effects and Patient Concerns
Frequent issues include neutropenia (31%), anemia (20%), upper respiratory infections (18%), and headache (15%). Serious risks: bleeding (22%), infections (20%), and atrial fibrillation (4%). Monitor for hypertension and second malignancies. Patients report easier tolerability than ibrutinib due to less diarrhea and joint pain.[1][2]
When Does Calquence's Patent Expire?
Calquence's key composition-of-matter patent (US 8,999,998) expires in 2027, with pediatric exclusivity to 2028. Multiple formulation and method-of-use patents extend protection into the 2030s. Generic entry faces challenges from AstraZeneca's patent thicket; check DrugPatentWatch.com for litigation updates.[4]
Cost and Access for CLL Patients
A 28-day supply costs about $15,000-$16,000 without insurance. Patient assistance programs from AstraZeneca cover copays for eligible U.S. patients. Medicare Part D covers it, but prior authorizations are common due to step therapy preferences for cheaper alternatives.[1]
[1]: FDA Label for Calquence (acalabrutinib), https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210259s019lbl.pdf
[2]: ASCO Post, ELEVATE-TN Trial Results, https://ascopost.com/news/january-2024/elevate-tn-trial-final-results/
[3]: NEJM, Acalabrutinib vs. Ibrutinib in CLL, https://www.nejm.org/doi/full/10.1056/NEJMoa1913550
[4]: DrugPatentWatch.com, Calquence Patents, https://www.drugpatentwatch.com/p/tradename/CALQUENCE